
    
      The study period per participant was approximatively 128 weeks broken down as follows:

        -  Screening period up to 4 weeks,

        -  108-week double-blind treatment period (approximatively 2 years)*,

        -  16-week post-treatment elimination follow-up period.

      '*' Participants successfully completing the week 108 visit were offered the opportunity to
      enter the optional long-term extension study LTS6050 - NCT00803049.
    
  